Mary Reumuth
Known title: CHIEF FINANCIAL OFFICERCIK: 0001710969
Associated companies
Transaction History
| KALA | ▼ Sell | Open Market | 967 | $793 | 10/23/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 32,230 | $27K | 10/22/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 3,631 | $15K | 6/24/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 2,850 | $11K | 6/3/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 1,706 | $13K | 1/6/2025 | View on chart |
| KALA | ▲ Buy | Grant | 10,100 | $0 | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 4,163 | $20K | 6/26/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 1,786 | $11K | 5/31/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 1,227 | $8K | 1/4/2024 | View on chart |
| KALA | ▲ Buy | Grant | 4,600 | $0 | 1/4/2024 | View on chart |
| KALA | ▲ Buy | Grant | 36,144 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 14,736 | — | 5/31/2023 | View on chart |
| KALA | ▲ Buy | Grant | 9,525 | $0 | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Open Market | 60 | $2K | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Open Market | 194 | $1K | 10/26/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 2,613 | $967 | 6/27/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 2,850 | $4K | 1/4/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 9,449 | $17K | 10/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform
KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.